CAMBREX CORPORATION acquired by PERMIRA

Permira, the global private equity firm, successfully completed the acquisition of Cambrex Corporation, a premier small molecule CDMO, in a take-private transaction that signaled a major consolidation move in the pharmaceutical services sector. The transaction was structured as a merger whereby shareholders received $60.00 in cash per share, representing a significant premium of 47.1% over the undisturbed share price. The deal allowed Cambrex to delist from the New York Stock Exchange and transition into a private entity, providing the management team with the long-term capital and operational flexibility required to further integrate its acquisitions and invest in global capacity expansion. Permira's investment thesis focused on capitalizing on the increasing trend of pharmaceutical companies outsourcing complex chemical manufacturing and analytical testing.